Srinath Sundararajan

420 total citations
29 papers, 287 citations indexed

About

Srinath Sundararajan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Srinath Sundararajan has authored 29 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Srinath Sundararajan's work include CAR-T cell therapy research (8 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Melanoma and MAPK Pathways (5 papers). Srinath Sundararajan is often cited by papers focused on CAR-T cell therapy research (8 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Melanoma and MAPK Pathways (5 papers). Srinath Sundararajan collaborates with scholars based in United States, South Korea and India. Srinath Sundararajan's co-authors include Baldassarre Stea, Haiyan Cui, Abhijeet Kumar, Joanne Jeter, Montaser Shaheen, Oscar B. Goodman, Paras Mehta, Nicholas J. Vogelzang, Chanté Karimkhani and Robert P. Dellavalle and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Srinath Sundararajan

28 papers receiving 281 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Srinath Sundararajan United States 9 191 113 72 66 41 29 287
Víctor Albarrán Spain 10 155 0.8× 74 0.7× 67 0.9× 68 1.0× 52 1.3× 17 284
Xin-Ke Zhang China 7 215 1.1× 118 1.0× 78 1.1× 65 1.0× 45 1.1× 9 359
Ayman Al‐Habeeb Canada 6 170 0.9× 79 0.7× 120 1.7× 74 1.1× 31 0.8× 7 313
Juan Esteban García-Robledo United States 9 102 0.5× 37 0.3× 77 1.1× 68 1.0× 42 1.0× 33 266
Chelsea Andrews United States 8 289 1.5× 120 1.1× 70 1.0× 31 0.5× 25 0.6× 17 320
K. Horwood Australia 6 238 1.2× 94 0.8× 60 0.8× 54 0.8× 35 0.9× 6 328
Anna Shvartsur United States 5 194 1.0× 65 0.6× 31 0.4× 124 1.9× 14 0.3× 6 317
Ahmed Raji Iraq 3 204 1.1× 68 0.6× 132 1.8× 97 1.5× 10 0.2× 8 319
Yumiko Higuchi Japan 10 167 0.9× 48 0.4× 166 2.3× 92 1.4× 54 1.3× 30 305
Constantine Sabalos United States 5 212 1.1× 88 0.8× 66 0.9× 57 0.9× 31 0.8× 7 310

Countries citing papers authored by Srinath Sundararajan

Since Specialization
Citations

This map shows the geographic impact of Srinath Sundararajan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srinath Sundararajan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srinath Sundararajan more than expected).

Fields of papers citing papers by Srinath Sundararajan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srinath Sundararajan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srinath Sundararajan. The network helps show where Srinath Sundararajan may publish in the future.

Co-authorship network of co-authors of Srinath Sundararajan

This figure shows the co-authorship network connecting the top 25 collaborators of Srinath Sundararajan. A scholar is included among the top collaborators of Srinath Sundararajan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srinath Sundararajan. Srinath Sundararajan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roe, Denise J., et al.. (2022). A single arm phase 2 study of talimogene laherparepvec in patients with low-risk invasive cutaneous squamous cell cancer. interim analysis.. Journal of Clinical Oncology. 40(16_suppl). e21583–e21583. 8 indexed citations
2.
3.
Sundararajan, Srinath, et al.. (2020). Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade. Case Reports in Dermatology. 12(2). 119–123. 3 indexed citations
4.
5.
Bracamonte, Erika, et al.. (2019). Primary Malignant Melanoma of the Bladder Treated by Robotic Partial Cystectomy and Immunotherapy. Journal of Endourology Case Reports. 5(4). 151–153. 3 indexed citations
6.
Lemole, Gerald M., et al.. (2019). Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review. Journal of the National Comprehensive Cancer Network. 17(10). 1148–1153. 4 indexed citations
7.
Mehta, Paras, et al.. (2019). Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies. 8(4). 51–51. 35 indexed citations
8.
Sundararajan, Srinath, et al.. (2019). Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib. SHILAP Revista de lepidopterología. 2019. 1–4. 4 indexed citations
9.
Abraham, Ivo, et al.. (2018). Clinical experience with talimogene laherparepvec in a melanoma population at a university based cancer center.. Journal of Clinical Oncology. 36(15_suppl). e21547–e21547. 1 indexed citations
10.
Karimkhani, Chanté, Bobby Y. Reddy, Robert P. Dellavalle, & Srinath Sundararajan. (2017). Novel therapies for unresectable and metastatic melanoma. BMJ. 359. j5174–j5174. 7 indexed citations
11.
Kumar, Abhijeet, et al.. (2017). Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacological Research. 123. 95–102. 52 indexed citations
12.
Mahadevan, Daruka, Monica Mita, Donald Richards, et al.. (2017). Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients. Cancer Chemotherapy and Pharmacology. 79(4). 681–688. 5 indexed citations
13.
Sundararajan, Srinath, Abhijeet Kumar, Neha Korde, & Amit Agarwal. (2016). Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics. Current Hematologic Malignancy Reports. 11(2). 102–110. 7 indexed citations
14.
Kumar, Abhijeet, Srinath Sundararajan, Soham D. Puvvada, & Daniel O. Persky. (2016). Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?. Current Treatment Options in Oncology. 17(9). 45–45. 1 indexed citations
15.
Sundararajan, Srinath, et al.. (2016). Cardiovascular Adverse Effects of Targeted Antiangiogenic Drugs: Mechanisms and Management. Future Oncology. 12(8). 1067–1080. 12 indexed citations
16.
Kumar, Abhijeet, José Guillen-Rodriguez, Jonathan H. Schatz, et al.. (2016). A Phase II, Open-Label Study of Bortezomib (Velcade®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas. Blood. 128(22). 1790–1790. 1 indexed citations
17.
Sundararajan, Srinath, et al.. (2016). Effect of histological subtype on overall survival in cutaneous melanoma: A Surveillance, Epidemiology, and End Result program (SEER) database review.. Journal of Clinical Oncology. 34(15_suppl). e21051–e21051. 1 indexed citations
18.
Sundararajan, Srinath, et al.. (2015). Poorly Differentiated Neuroendocrine Tumor of the Rectum Coexistent with Giant Rectal Villous Adenoma Presenting as McKittrick-Wheelock Syndrome. SHILAP Revista de lepidopterología. 2015. 1–4. 8 indexed citations
19.
Sundararajan, Srinath & Nicholas J. Vogelzang. (2014). Chemotherapy in the Treatment of Prostate Cancer — The Past, the Present, and the Future. 10(6). 4 indexed citations
20.
Sundararajan, Srinath, et al.. (2011). The relevance of BRCA genetics to prostate cancer pathogenesis and treatment.. PubMed. 9(10). 748–55. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Víctor Albarrán Breakdown of academic impact, for papers by Xin-Ke Zhang Breakdown of academic impact, for papers by Ayman Al‐Habeeb Breakdown of academic impact, for papers by Juan Esteban García-Robledo Breakdown of academic impact, for papers by Chelsea Andrews Breakdown of academic impact, for papers by K. Horwood Breakdown of academic impact, for papers by Anna Shvartsur Breakdown of academic impact, for papers by Ahmed Raji Breakdown of academic impact, for papers by Yumiko Higuchi Breakdown of academic impact, for papers by Constantine Sabalos
Rankless by CCL
2026